Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer

Thursday, September 13, 2007 General News
Email Print This Page Comment bookmark
Font : A-A+

BETHESDA, Md., Sept. 12 Micromet, Inc.(Nasdaq: MITI), a biopharmaceutical company developing novel, proprietaryantibodies for the treatment of cancer, inflammation and autoimmune diseases,announced today the appointment of Mark Reisenauer as Senior Vice Presidentand Chief Commercial Officer.

"Mark brings significant commercial expertise in oncology to Micromet at atime in our corporate development when the profile of our lead programs isemerging and our pipeline is maturing. His experience will be highly valuablein further defining our targeted indications, patient population andregulatory strategy for our clinical stage programs," commented ChristianItin, Ph.D., President and Chief Executive Officer of Micromet. "Mark willalso strongly impact the development and partnering strategy of our BiTEantibody platform and antibody portfolio and we are looking forward to hiscontributions to shape the commercial strategy of the company."

"I am delighted to join Micromet with its unique antibody pipeline anddevelopment programs. I am particularly excited by the potential of the BiTEantibody platform which promises to bring a new, efficacious treatmentmodality to cancer patients," Mark Reisenauer added. "The clinical responsesseen in late stage, refractory NHL patients, and the profound effects MT103showed on eliminating lymphoma cells from bone marrow indicate a uniqueproduct profile, positioning MT103 for use in advanced stage cancer but alsopotentially as consolidation therapy in patients with a variety of B celltumors. Another promising compound, adecatumumab, a human antibody targetingEpCAM, was shown to improve the prognosis of breast cancer patients with highlevels of EpCAM and may provide a unique approach to fight the recurrence ofsolid tumors."

Mark Reisenauer joins Micromet from Abbott, where he was the GeneralManager of the Oncology Franchise from 2002 to 2006 and most recentlyDivisional Vice President and General Manager of the Neuroscience franchise.Before joining Abbott, Mark was the Director of Marketing for Breast Cancer(Portfolio Lead) and the Director of Breast Cancer Products at Pharmacia from1999 to 2002. From 1997 to 1999 Mark was the Associate Director of OncologyGlobal Marketing at Bristol-Myers Squibb and from 1988 to 1999 held variouspositions in sales and oncology marketing at Zeneca. Mark holds a BA degree inPolitical Science from the University of Wisconsin.

About Micromet, Inc. (www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel,proprietary antibodies for the treatment of cancer, inflammation andautoimmune diseases. Three of its antibodies are in clinical development.MT103 (MEDI-538), the first clinically validated BiTE(R) antibody inMicromet's product pipeline, is being evaluated in a phase 1 clinical trialfor the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodiesrepresent a new class of antibodies that activate a patient's own cytotoxic Tcells to eliminate cancer cells. Micromet is developing MT103 in collaborationwith AstraZeneca's subsidiary MedImmune, Inc. The second clinical stageantibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAMexpressing tumors. Adecatumumab is being developed by Micromet incollaboration with Merck Serono in a phase 1b clinical trial evaluating MT201in combination with docetaxel for the treatment of patients with metastaticbreast cancer. The third clinical stage antibody is D93 (TRC093), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cellgrowth by binding cleaved collagen. D93, which is currently tested in a phase1 clinical trial, is licensed to TRACON Pharmaceuticals, Inc. and is beingdeveloped for the treatment of patients with cancer and age-related maculardegeneration. In addition, Micromet has established a collaboration withNycomed for the development and commerciali

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store